Reports
Reports
Sale
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview – 8 Major Markets
3.1 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023)
3.2 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 United States
7.1.1.2 United Kingdom
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 United States
7.1.2.2 United Kingdom
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment seeking rate, by Country
7.1.3.1 United States
7.1.3.2 United Kingdom
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Landscape – 8 Major Markets
8.1 Attention Deficit Hyperactivity Disorder (ADHD) Treatment: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Attention Deficit Hyperactivity Disorder (ADHD) Treatment: Product Landscape
8.2.1 Analysis by Treatment Type
8.2.2 Analysis by Age Group
8.2.3 Analysis by Route of Administration
9 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentation (2017-2032) - 8 Major Markets
12.1 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment Type
12.1.1 Market Overview
12.1.2 Stimulants
12.1.2.1 Amphetamine
12.1.2.2 Methylphenidate
12.1.2.3 Dextroamphetamine
12.1.2.4 Dexmethylphenidate
12.1.2.5 Lisdexamfetamine Dimesylate
12.1.3 Non-Stimulants
12.1.3.1 Atomoxetine
12.1.3.2 Bupropion
12.1.3.3 Guanfacine
12.1.3.4 Clonidine
12.2 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
12.2.1 Market Overview
12.2.2 Adult
12.2.3 Children
12.3 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
12.3.1 Market Overview
12.3.2 Male
12.3.3 Female
12.4 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
12.4.1 Market Overview
12.4.2 Hospital Pharmacies
12.4.3 Retail Pharmacies
12.4.4 Others
12.5 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032)
13.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023)
13.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
13.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment T ype
13.3.1 Market Overview
13.3.2 Stimulants
13.3.2.1 Amphetamine
13.3.2.2 Methylphenidate
13.3.2.3 Dextroamphetamine
13.3.2.4 Dexmethylphenidate
13.3.2.5 Lisdexamfetamine Dimesylate
13.3.3 Non-Stimulants
13.3.3.1 Atomoxetine
13.3.3.2 Bupropion
13.3.3.3 Guanfacine
13.3.3.4 Clonidine
13.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
13.4.1 Market Overview
13.4.2 Adult
13.4.3 Children
13.5 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
13.5.1 Market Overview
13.5.2 Male
13.5.3 Female
13.6 United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
13.6.1 Market Overview
13.6.2 Hospital Pharmacies
13.6.3 Retail Pharmacies
13.6.4 Others
14 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032)
14.1 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Stimulants
14.3.2.1 Amphetamine
14.3.2.2 Methylphenidate
14.3.2.3 Dextroamphetamine
14.3.2.4 Dexmethylphenidate
14.3.2.5 Lisdexamfetamine Dimesylate
14.3.3 Non- Stimulants
14.3.3.1 Atomoxetine
14.3.3.2 Bupropion
14.3.3.3 Guanfacine
14.3.3.4 Clonidine
14.4 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
14.4.1 Market Overview
14.4.2 Adult
14.4.3 Children
14.5 EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
14.5.1 Market Overview
14.5.2 Male
14.5.3 Female
14.6 EU-4 and United Kingdom ttention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
14.6.1 Market Overview
14.6.2 Hospital Pharmacies
14.6.3 Retail Pharmacies
14.6.4 Others
15 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
15.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023)
15.2 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
15.3 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment T ype
15.3.1 Market Overview
15.3.2 Stimulants
15.3.2.1 Amphetamine
15.3.2.2 Methylphenidate
15.3.2.3 Dextroamphetamine
15.3.2.4 Dexmethylphenidate
15.3.2.5 Lisdexamfetamine Dimesylate
15.3.3 Non-Stimulants
15.3.3.1 Atomoxetine
15.3.3.2 Bupropion
15.3.3.3 Guanfacine
15.3.3.4 Clonidine
15.4 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
15.4.1 Market Overview
15.4.2 Adult
15.4.3 Children
15.5 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
15.5.1 Market Overview
15.5.2 Male
15.5.3 Female
15.6 Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
15.6.1 Market Overview
15.6.2 Hospital Pharmacies
15.6.3 Retail Pharmacies
15.6.4 Others
16 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
16.1 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) Historical Value (2017-2023)
16.2 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) Forecast Value (2024-2032)
16.3 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment T ype
16.3.1 Market Overview
16.3.2 Stimulants
16.3.2.1 Amphetamine
16.3.2.2 Methylphenidate
16.3.2.3 Dextroamphetamine
16.3.2.4 Dexmethylphenidate
16.3.2.5 Lisdexamfetamine Dimesylate
16.3.3 Non-Stimulants
16.3.3.1 Atomoxetine
16.3.3.2 Bupropion
16.3.3.3 Guanfacine
16.3.3.4 Clonidine
16.4 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
16.4.1 Market Overview
16.4.2 Adult
16.4.3 Children
16.5 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
16.5.1 Market Overview
16.5.2 Male
16.5.3 Female
16.6 India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
16.6.1 Market Overview
16.6.2 Hospital Pharmacies
16.6.3 Retail Pharmacies
16.6.4 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 Japan PMDA
17.1.4 India CDSCO
17.1.5 Others
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Grants Analysis
19.1 Analysis by Year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Strategic Initiatives
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 Takeda Pharmaceutical Company Limited
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Company News and Development
22.2.5 Certifications
22.3 Aytu BioPharma, Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Company News and Development
22.3.5 Certifications
22.4 Eli Lilly and Company
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Company News and Development
22.4.5 Certifications
22.5 Pfizer Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Company News and Development
22.5.5 Certifications
22.6 Noven Pharmaceuticals Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Company News and Development
22.6.5 Certifications
22.7 Supernus Pharmaceuticals, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Company News and Development
22.7.5 Certifications
22.8 Johnson & Johnson Servi ces Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Company News and Development
22.8.5 Certifications
22.9 Novartis A G
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Company News and Development
22.9.5 Certifications
22.10 Curemark, LLC
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Company News and Development
22.10.5 Certifications
22.11 GlaxoSmithKline Plc
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Company News and Development
22.11.5 Certifications
22.12 Highland Therapeutics Inc.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Company News and Development
22.12.5 Certifications
23 Attention Deficit Hyperactivity Disorder (ADHD) Treatment Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.